ARPA-H launched ADVOCATE, a program meant to build FDA-authorized agentic AI tools, and named UpDoc, Tempus AI, and Atman Health as participants for heart disease use cases. The effort builds on ARPA-H’s push for faster translation of breakthrough health technologies. The program is framed around creating AI systems capable of supporting clinical decision-making with appropriate regulatory and authorization pathways. For industry players, the announcement clarifies that agentic capabilities are moving from prototypes toward compliance-driven deployment plans. By focusing on heart disease—where imaging, labs, EHR data, and guideline-driven decision pathways create structured opportunities for automation—ADVOCATE may accelerate development of tools that integrate data retrieval, reasoning, and actionable outputs. The selection also signals continued government demand for multi-organization partnerships that combine platform-level AI with data and clinical workflow expertise.